Dr. Paul Nunzio DeSantis, Pharm.D
Event-driven, research analyst, hedge fund analyst, biotech

The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians

This article will be the first contribution in a series of reports that will track the rapid developments at Intercept Pharmaceuticals (NASDAQ:ICPT) throughout 2014. This report will only cover the most recent developments and summarize expert commentary regarding OCA from a conference call this past weekend. A more comprehensive report will be written when full top-line data from the FLINT trial and other trials are released. Once this data becomes available, it will provide insight into how OCA alters the pathogenesis of NASH. Depending on OCA's pharmacodynamic properties (what the drug does to the body), we can then construct a sales model and compare it to Wall Street's expectations. Future reports will provide a comprehensive overview of Intercept's...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details